Results 41 to 50 of about 4,078 (132)

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor

Endocrine Oncology
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary,
Katherine I Wolf, Zhonglin Lu, Elizabeth A Hesseltine, Ka-Kit Wong, Francis P Worden, Tobias Else   +5 more
doaj   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

World Journal of Nuclear Medicine, 2022
Background This study was conducted to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs).
Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, Mohammad Reza Ravanbod, Esmail Jafari, AbdulLatif Amini, Habibollah Dadgar, Mehdi Mahmoudpour, Iraj Nabipour, Narges Jokar, Majid Assadi   +10 more
doaj   +1 more source

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Endocrine Connections, 2019
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide ...
G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò   +10 more
doaj   +1 more source

Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Primary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features
Hamid Zeinali Nezhad, Shima Yaghoobi, Nazanin Zeinali Nezhad, Amirhossein Shahpar, Abtin Malekpour Afshar, Mina Bagherijamebozorgi   +5 more
wiley   +1 more source

Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images [PDF]

Journal of Biomedical Physics and Engineering
Background: Radiomics is the computation of quantitative image features extracted from medical imaging modalities to help clinical decision support systems, which could ultimately meliorate personalized management based on individual characteristics ...
Baharak Behmanesh, Akbar Abdi-Saray, Mohammad Reza Deevband, Mahasti Amoui, Hamid Reza Haghighatkhah   +4 more
doaj   +1 more source

Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2‐Epigenetic Circuit

Advanced Science, Volume 13, Issue 20, 9 April 2026.
Our study reveals a novel mechanism of a positive regulatory circuit between Cav1.2 and H3K27ac for pancreatic neuroendocrine neoplasms (pNENs) progression. Cav1.2 is identified as a crucial target for promoting disease progression and correlates with malignant behaviors, which are remarkably inhibited by the administration of calcium channel blockers (
Yangyinhui Yu, Qiongcong Xu, Jinzhao Xie, Mingjian Ma, Xitai Huang, Yinhao Shi, Jiawei Zhou, Enliang Zhu, Ziyi Zhao, Ning Zhang, Zhide Liu, Jingyuan Ye, Xiaoyu Yin   +12 more
wiley   +1 more source

Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center

Indian Journal of Endocrinology and Metabolism
Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT).
David Mathew, Saumya S. Sunny, Justin Benjamin, Junita R. John, Felix K. Jebasingh, Josh T. Georgy, Ashish Singh, Regi Oommen   +7 more
doaj   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, EarlyView.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source